Atara Biotherapeutics Announces $15 Million Registered Direct Offering
09 January 2024 - 1:00AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
it has entered into a definitive agreement for the issuance and
sale of pre-funded warrants to purchase 27,272,727 shares of its
common stock at a purchase price of $0.55 per pre-funded warrant
share in a registered direct offering to entities affiliated with
an existing institutional investor. The pre-funded warrants will
have an exercise price of $0.0001 per share, and will be
immediately exercisable upon issuance. The offering is expected to
close on or about January 10, 2024, subject to the satisfaction of
customary closing conditions.
The gross proceeds to Atara from the offering are expected to be
$15 million, before deducting estimated offering expenses payable
by Atara. Atara currently intends to use the net proceeds from the
offering for working capital and general corporate purposes.
The securities described above are being offered by Atara
pursuant to a shelf registration statement on Form S-3 (No.
333-275256), including a base prospectus, that was previously filed
by Atara with the U.S. Securities and Exchange Commission (the
“SEC”) and was declared effective on November 13, 2023. A
prospectus supplement containing additional information relating to
the offering will be filed with the SEC and will be available on
the SEC’s website located at https://www.sec.gov/.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to
develop off-the-shelf cell therapies for difficult-to-treat cancers
and autoimmune conditions that can be rapidly delivered to patients
within days. With cutting-edge science and differentiated approach,
Atara is the first company in the world to receive regulatory
approval of an allogeneic T-cell immunotherapy. Our advanced and
versatile Epstein-Barr virus (EBV) T-cell platform does not require
T-cell receptor or HLA gene editing and forms the basis of a
diverse portfolio of investigational therapies that target EBV, the
root cause of certain diseases, in addition to next-generation
AlloCAR-Ts designed for best-in-class opportunities across a broad
range of hematological and B-cell driven autoimmune diseases. Atara
is headquartered in Southern California. For more information,
visit atarabio.com and follow @Atarabio on X (formerly known as
Twitter) and LinkedIn.
Forward-Looking Statements
This press release contains or may imply “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. For example, forward-looking statements
include statements regarding the completion, timing and size of the
offering and the anticipated use of proceeds of the offering.
Because such statements deal with future events and are based on
Atara’s current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
Atara could differ materially from those described in or implied by
the statements in this press release. These forward-looking
statements are subject to risks and uncertainties, including
without limitation risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related
to the offering, as well as those discussed in Atara’s filings with
the SEC, including in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of the prospectus supplement and Atara’s most
recently filed periodic reports on Form 10-K and Form 10-Q and
subsequent filings and in the documents incorporated by reference
therein. Except as otherwise required by law, Atara disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a
result of new information, future events or circumstances or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240107077138/en/
Investor and Media Relations: Alex Chapman Vice
President, Corporate Communications & Investor Relations (805)
456-4772 achapman@atarabio.com
Jason Awe, Ph.D. Senior Director, Corporate Communications &
Investor Relations (805) 217-2287 jawe@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024